The RDTC PGx Governance Principles Signal a New Era — What This Means for UKIPN

The Regional Drug and Therapeutics Centre (RDTC) has released a landmark document: Principles for embedding pharmacogenomics into NHS medicines governance.

This guidance is more than a technical resource, it represents a fundamental shift in the national conversation. For years, the focus in UK pharmacogenomics (PGx) has been on why we should integrate PGx into routine care. The RDTC guidance makes it clear:

We are now firmly in the territory of "how".

Why this matters

The document positions PGx as a key component of safe, effective prescribing. It highlights:

• The need for robust governance structures

• The importance of equitable and standardised implementation

• The role of medicines committees in overseeing PGx integration

• The operational, clinical, and safety considerations that must be addressed

• The expectation that PGx will expand significantly over the next decade

This is not speculative.

This is practical, operational, and grounded in NHS reality.

What this means for UKIPN

1. The NHS is preparing for real‑world PGx implementation

The guidance explicitly frames PGx as part of routine medicines governance — not a research add‑on, not a pilot curiosity, but a core prescribing consideration.

2. Industry is now part of the implementation conversation

To embed PGx safely and consistently, the NHS needs:

• Clear evidence

• Usable data

• Practical workflows

• Interoperable digital solutions

• Training and workforce support

• Governance frameworks

These are areas where UKIPN members can directly contribute.

3. The focus is shifting to operationalisation

The RDTC guidance highlights the need for collaboration across:

• Medicines committees

• Genomic Medicine Service Alliances

• Informatics teams

• Clinical genetics

• Pharmacy and prescribing leadership

This is the ecosystem where UKIPN operates — and where industry expertise is essential.

4. Data gaps are being surfaced early

The guidance implicitly raises questions about:

• Real‑world outcomes

• Safety monitoring

• Equity of access

• Workforce readiness

• Integration with the Single Patient Record

• Funding flows and commissioning

These are exactly the areas where UKIPN can help shape national thinking.

The publication of these principles marks a new phase for PGx in the UK.

We are no longer debating whether PGx belongs in the NHS.

That question has been answered.

The question now is:

How do we implement PGx safely, consistently, and at scale?

And that is where the UK Industry Pharmacogenomics Network has a unique and essential role.

Our task now is to:

• Support NHS governance structures

• Provide clarity on evidence and data needs

• Help design scalable implementation models

• Ensure industry and NHS work in partnership

• Champion equitable, standardised PGx pathways

PGx is moving from aspiration to action.

The "how" is now the work — and UKIPN is ready to lead it.